Category Archives: Cf

Polymorphonuclear neutrophils (PMNs) play an important role in both host defense and noninfectious inflammation. Failure to stop the inflammatory response and its causes can feed the excessive inflammation seen in many human disorders, including cystic fibrosis (CF), an autosomal recessive genetic disease caused by mutations in the CF transmembrane conductance regulator. For a study, researchers focused on the molecular basis for, and clinical repercussions of, abnormalities in the MPO-H2O2-Cl system caused by CFs impaired Cl transport. They first discussed how the MPO-H2O2-Cl system participates in host defense and inflammation resolution in healthy PMNs, and then looked at how a defective MPO-H2O2-Cl system contributes to the increased susceptibility to infection and dysregulated inflammation associated with CF clinical manifestations.

Multiple end organs are affected by CF, with persistent bacterial infection and chronic neutrophilic inflammation in the airways dominating the clinical picture. PMNs have a number of antimicrobial mechanisms to delay or kill invading microorganisms contained in their phagosomes to fit the varied microbial challenges that they may face. PMN defense systems are notable for their capacity to produce hypochlorous acid, a powerful microbicide, by combining oxidants produced by the NADPH oxidase with myeloperoxidase (MPO) released from azurophilic granules in the presence of chloride (Cl). MPO-H2O2-Cl system products oxidize sensitive biomolecules and promote powerful antibacterial activity against many, but not all, potential human infections.

Individuals with defects in any component of the MPO-H2O2-Cl system, as seen in chronic granulomatous disease of MPO deficiency, have increased rates or severity of infection and signs of dysregulated inflammatory responses, highlighting the importance of the MPO-H2O2-Cl system in optimal host defense and proper regulation of inflammation.

Reference:ashpublications.org/blood/article-abstract/139/17/2622/484179/Neutrophil-dysfunction-in-the-pathogenesis-of?redirectedFrom=fulltext

Read more here:

Neutrophil Dysfunction in the Pathogenesis of Cystic Fibrosis (CF) - Physician's Weekly

Equities analysts expect CF Industries Holdings, Inc. (NYSE:CF Get Rating) to report earnings per share (EPS) of $6.16 for the current quarter, according to Zacks. Five analysts have provided estimates for CF Industries earnings, with estimates ranging from $4.44 to $7.29. CF Industries posted earnings of $1.14 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 440.4%. The business is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that CF Industries will report full-year earnings of $18.94 per share for the current financial year, with EPS estimates ranging from $16.66 to $22.73. For the next fiscal year, analysts expect that the business will report earnings of $14.26 per share, with EPS estimates ranging from $9.24 to $18.60. Zacks EPS calculations are an average based on a survey of research firms that follow CF Industries.

CF Industries (NYSE:CF Get Rating) last issued its earnings results on Wednesday, May 4th. The basic materials company reported $4.21 earnings per share for the quarter, hitting analysts consensus estimates of $4.21. The company had revenue of $2.87 billion for the quarter, compared to analysts expectations of $2.62 billion. CF Industries had a net margin of 19.73% and a return on equity of 35.04%. The firms revenue was up 173.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.70 earnings per share.

Shares of CF Industries stock traded down $4.56 during trading on Friday, hitting $95.79. 3,684,379 shares of the stock were exchanged, compared to its average volume of 3,241,641. The stocks fifty day moving average is $101.09 and its 200 day moving average is $81.05. The stock has a market cap of $19.98 billion, a PE ratio of 12.34, a P/E/G ratio of 0.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.50 and a current ratio of 1.72. CF Industries has a 12 month low of $43.19 and a 12 month high of $113.49.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 31st. Stockholders of record on Monday, May 16th will be given a dividend of $0.40 per share. This is a positive change from CF Industriess previous quarterly dividend of $0.30. The ex-dividend date of this dividend is Friday, May 13th. This represents a $1.60 annualized dividend and a dividend yield of 1.67%. CF Industriess dividend payout ratio (DPR) is 20.62%.

In other news, VP Richard A. Hoker sold 4,085 shares of the stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $93.93, for a total value of $383,704.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan L. Menzel sold 20,000 shares of the stock in a transaction that occurred on Monday, February 28th. The stock was sold at an average price of $80.35, for a total transaction of $1,607,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,333,463 shares of company stock valued at $107,631,042. Insiders own 0.42% of the companys stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in CF Industries by 0.4% during the first quarter. Vanguard Group Inc. now owns 25,747,358 shares of the basic materials companys stock valued at $2,653,523,000 after acquiring an additional 94,482 shares in the last quarter. State Street Corp raised its position in CF Industries by 0.5% during the fourth quarter. State Street Corp now owns 9,390,450 shares of the basic materials companys stock valued at $664,656,000 after acquiring an additional 49,793 shares in the last quarter. Bank of New York Mellon Corp raised its position in CF Industries by 0.3% during the third quarter. Bank of New York Mellon Corp now owns 5,922,239 shares of the basic materials companys stock valued at $330,579,000 after acquiring an additional 15,311 shares in the last quarter. Geode Capital Management LLC raised its position in CF Industries by 8.3% during the fourth quarter. Geode Capital Management LLC now owns 5,040,352 shares of the basic materials companys stock valued at $356,069,000 after acquiring an additional 387,547 shares in the last quarter. Finally, Glendon Capital Management LP raised its position in CF Industries by 17.1% during the third quarter. Glendon Capital Management LP now owns 4,958,222 shares of the basic materials companys stock valued at $276,768,000 after acquiring an additional 722,745 shares in the last quarter. 93.00% of the stock is owned by institutional investors and hedge funds.

CF Industries Company Profile (Get Rating)

CF Industries Holdings, Inc manufactures and sells hydrogen and nitrogen products for energy, fertilizer, emissions abatement, and other industrial activities worldwide. Its principal products include anhydrous ammonia, granular urea, urea ammonium nitrate, and ammonium nitrate products. The company also offers diesel exhaust fluid, urea liquor, nitric acid, and aqua ammonia products; and compound fertilizer products with nitrogen, phosphorus, and potassium.

See Also

Get a free copy of the Zacks research report on CF Industries (CF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CF Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CF Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:

CF Industries Holdings, Inc. (NYSE:CF) Expected to Announce Earnings of $6.16 Per Share - Defense World

CF Montreal have become one of the more entertaining teams to watch in MLS this season. With manager Wilfried Nancys fluid 3-4-3 shape, their desire to keep the ball, and quality players sprinkled all over the field, Montreal check a lot of the boxes that fun and good teams tend to check.

Theres one more box, though, that theyre checking in 2022: Trusting and developing an extremely talented young player; 19-year-old homegrown Ismal Kon.

Kon, a central midfielder, is in the midst of an impressive first season in MLS. After an injury to Samuel Piette freed up minutes in midfield, he entered Montreals starting lineup in their second game of the season, a home match against Santos Laguna in the CONCACAF Champions League. Kon has since started all but three games for Nancy and has even played twice for Canadas mens national team. Kon also has multiple European training stints under his belt, one in Belgium and one in Italy with Bologna.

Lets dive into what makes Kon so special.

If you watch even just a few seconds of Kons game tape, the first thing that will immediately stand out is his build. Standing at a thin six-foot-2, he has an unusual frame for a soccer player, but it does provide unique advantages. His long legs and athletic ability allow Kon to have some impressive speed. He can cover ground on both sides of the ball and regularly uses his range to impact the game.

When Montreal have the ball, Kon plays as the more advanced member of Nancys double pivot, positioned slightly ahead of Victor Wanyama in central midfield. Kons long frame and his ground coverage make him a good fit for that advanced midfield role. In possession, its clear to the naked eye that Kon loves to stride forward and involve himself in Montreals attacking play more so than others in that position. And once hes in those positions, data shows hes generally a pretty effective contributor. According to FBref, Kon is more involved than most MLS central midfielders when it comes to the attack. His 0.15 non-penalty goals per 90 minutes and his 0.12 expected assists per 90 minutes put him in the 81st and 74th percentile among MLS midfielders over the last year.

Kons lone goal of the year is a great representation of how he influences Montreals attack. In the first half of Montreals 3-3 draw with Atlanta United in March, Kon switched the point of attack from right to left before making a lovely late-arriving run that started in midfield and ended near the penalty spot. Even with a 10-yard head start, Atlanta defensive midfielder Ozzie Alonso couldnt keep up with him. Now, Alonso, uh, isnt the quickest player when healthy at the stage of his MLS career, but its still an impressive run.

Covering that much ground in such a small amount of time is nothing short of incredible.

Even if he doesnt contribute directly to the play, Kons ability to move into attacking spaces has also helped his team disrupt opposing defenses. On this play from last month, Kon doesnt get on the end of the pass, but his run comes out of nowhere to draw defenders away from the ball-carrier for just enough time to allow an actual play to develop. With better timing (or more involved teammates), Kons run could easily have led to a Montreal possession in opposition territory with the opposing defenders on the back foot.

Kon offers value with the ball at his feet as well, having proven to be an extremely aggressive dribbler when in possession. Per FBref, he averages 1.31 successful dribbles per 90 minutes which puts him in the 81st percentile among midfielders in MLS. Kons close control combined with his aforementioned acceleration makes it difficult for opposing defenders to stop him with the ball at his feet. It takes Kon a little too long to turn in this clip because he doesnt check his shoulders soon enough, but once he has the ball with any kind of space in front, hes gone. He dribbles his way through Atlanta Uniteds midfield line and moves the ball out to the wing for one of his attacking teammates.

Kons range comes in handy when theyre defending, too. Almost like a free safety in American football, Kon can hang back in defensive transition before taking a few short steps (for him) and intercepting the ball. You can see that on this play, where he steps in front of Matheus Rossetto to stop an Atlanta counter attack.

As Kon continues to gain on-field experience and learns to deploy these abilities consistently and in the right moments, his speed and range will only become more difficult for opposing teams to deal with.

While Kon is a brilliant young player, there are a couple of key areas of his game that need improvement, particularly in possession.

As shown earlier, Kon doesnt always check his shoulders before receiving the ball, or at least he doesnt always check them at the right time. Because hes sometimes unaware of who and what is around him, Kon has to focus on getting his bearings on the ball instead of picking out a quality pass. Per FBref, the 19-year-old is in just the 17th percentile among MLS midfielders in passes attempted per 90 minutes. According to American Soccer Analysiss Goals Added metric, Kon is one of the weakest passers on his team.

Hes not involved enough in Montreals possession and when he is involved, the outcome isnt always great. As an example, Kon couldve turned away from pressure and helped his team switch the point of attack over to the far side on this play. Instead, he takes a touch back towards the near sideline and forces a teammate to play a hopeful long ball.

Refining his game as he receives the ball (and directly afterwards) will turn Kon into a better and more well-rounded player.

One other area that Kon should improve is his decision-making in the final third, especially with his shot selection. Kon loves to shoot from outside the box. While long shots can be useful, they often function as a wasteful end to a potentially valuable possession. According to FBref, the midfielder averages 0.03 xG per shot. Thats a very low number that puts him in just the 13th percentile among MLS midfielders. You can see his teammates frustration when he takes this shot at a tough angle from 25-yards out. The shot was blocked and turned possession over to the Philadelphia Union.

If Kon can improve his passing in possession and tighten up his shot selection, 2022 might be a memorable year for the 19-year-old. Kon could feature for Canada at the World Cup and he could be in line for a move from Montreal over to a European club later this year as well.

For now, though, Kon is one of the most entertaining and unique players in MLS and for a teenager, thats no small feat.

(Photo: David Kirouac/Icon Sportswire via Getty Images)

Read the original here:

CF Montreals Ismal Kon is showing impressive promise early this MLS season - The Athletic

May 16, 2022

John ODonnell was diagnosed with Cystic Fibrosis (CF) at six months old in 1960. He has been a patient at London Health Sciences Centres (LHSC) CF Clinic for about 25 years. John has experienced a variety of CF treatments over the decades. When I was first diagnosed I would sleep in an oxygen tent every night. The tent would be pumped with mist that had antibiotics in it and I slept in that until I was 13 years old. As technology and information changed, so did approaches to treatment. When it was discovered that mist wasnt good for the lungs, that being in dry air was actually helpful for those with CF, the doctor ended that treatment, says John.

Before the pandemic, CF doctors from LHSC would visit the Sault Area Hospital out-patient clinic two or three times a year to meet with John to monitor his condition. I live in Sault Ste. Marie and Ive always appreciated being able to meet with my CF doctors near my home. Because of the pandemic, the appointments switched to over the phone first, and now we have our appointments through TeleMed, explains John. From the various doctors Ive had and the constant support from Tracy, who has known me for all this time they know me and send me for tests and follow up accordingly the care that Ive received from LHSC has been phenomenal.

John started taking Trikafta in March 2021. He wasnt doing well prior to being prescribed the medication and was one of the patients put on Trikafta for compassionate reasons before the drug was widely approved for use by Health Canada. At the time, there were no other treatment options available to John. I was coughing up blood once or twice a week, I was down to 30% lung function my prognosis was not good. I was coming to the end of my runway as I say, John shares. When you have chronic, deadly illness I was thinking about death anyway. It was a slow process up to that point. I was 60. Who knows when its your time? You never really know.

As Johns lungs deteriorated, he had to give up the amount of activity he enjoyed participating in such as back country skiing, snowshoeing, and triathlons. When he was younger he competed in iron man competitions and climbed to a base camp on Mount Everest. It was a slow process over the years, and John says it was difficult in some ways and not in others. When I was born, I was given a life expectancy of around five years, and zoom ahead to today and its around 55 years old. I always knew my life expectancy was going to be shorter than average.

John says, When I told I was going to get medication, I was hoping for something good. And I never imagined this good. My lung function increased to around 45% from 30%, my sleep improved because I was no longer waking up coughing. Now I sleep just like everyone else without those interruptions. I dont have normal lungs - Ive had damage from pneumonias over the years - but now I have enough lung function that I can do a lot of things I enjoy doing. This drug is a break through. As far as CF treatment goes, this is a huge step.

John noticed results right away. The medication started loosening the phlegm in his lungs within about 12 hours. He was coughing a lot so much that he got a headache but he was coughing up mucous and by the third day, he was clear. I snowshoed for 90 minutes that day on a very hilly trail. Before taking the medication, I was thinking I was going to die, I couldnt see any way forward, but I didnt see this coming. This medication was a life changing experience.

Going forward, John will continue to have three or four check-ins a year to make sure hes stable and gets pulmonary function tests every three months to monitor how his lungs are doing. He sees great value in both call and in-person visits since he is stable. If he has any issues, he feels comfortable contacting Tracy in email because she gets back within minutes. Shes very attentive. I can pick up the phone and call her - the care they provide at the CF clinic is incredible.

Three years ago, I tried to cross country ski and I was too out of breath. I came home, sat down, and had a little cry, John describes, To compare, after the first week on this medication, I had another cry. It was a good cry. And I could cross country ski again. I always had some hope and I was reasonable in my expectations but I wasnt expecting this. Its a terminal illness and I know Im not going to escape this. But as far as treatments go to help improve my quality of life, I couldnt ask for anything better.

John continues, Theres an analogy I use for how this treatment has made me feel: It feels like if you went to bed one night and had zero dollars in your bank account and you woke up the next day and someone put a million dollars in there.

Read more from the original source:

Living with Cystic Fibrosis: A CF patient experience story | LHSC - London Health Sciences Centre

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Continue reading here:

Film produced by CF native to be shown at Micon Cinemas - Leader-Telegram

ReportLinker

CF & CFRP Market Research Report by Carbon Fiber Materials (PAN-based, Pitch-based, and Rayon-based), Resin Type, Manufacturing Process, End-use Industry, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

New York, May 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "CF & CFRP Market Research Report by Carbon Fiber Materials, Resin Type, Manufacturing Process, End-use Industry, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06276891/?utm_source=GNW

The Global CF & CFRP Market size was estimated at USD 13.80 billion in 2021 and expected to reach USD 15.72 billion in 2022, and is projected to grow at a CAGR 14.21% to reach USD 30.63 billion by 2027.

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:This research report categorizes the CF & CFRP to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Carbon Fiber Materials, the market was studied across PAN-based, Pitch-based, and Rayon-based.

Based on Resin Type, the market was studied across Thermoplastic Resin and Thermosetting Resin.

Based on Manufacturing Process, the market was studied across Compression Molding, Filament Winding, Injection Molding, Lay-up, Others, Pultrusion, and Resin Transfer Molding.

Based on End-use Industry, the market was studied across Aerospace & Defense, Automotive, Civil Engineering, Electrical & Electronics, Marine, Medical, Others, Pipe & Tank, Sportswear & Sports Equipment, and Wind Energy.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for CF & CFRP market considering the current update on the conflict and its global response.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the CF & CFRP Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitors strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global CF & CFRP Market, including Aeron Composite Pvt. Ltd., Crosby Composites, DowAksa, ELG Carbon Fibre Ltd, Formosa Plastics Corporation, Gurit, Hexcel Corporation, HYOSUNG., Kemrock Industries and Exports Limited, Koninklijke Ten Cate bv, KUREHA CORPORATION, Mitsubishi Chemical Holding Corporation, Nippon Graphite Fiber Corporation, Plasan Carbon Composites, ROSATOM State Corporation, SGL Group, Sigmatex., Solvay SA, TEIJIN LIMITED., TORAY INDUSTRIES, INC, and UMATEX.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global CF & CFRP Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global CF & CFRP Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global CF & CFRP Market?4. What is the competitive strategic window for opportunities in the Global CF & CFRP Market?5. What are the technology trends and regulatory frameworks in the Global CF & CFRP Market?6. What is the market share of the leading vendors in the Global CF & CFRP Market?7. What modes and strategic moves are considered suitable for entering the Global CF & CFRP Market?Read the full report: https://www.reportlinker.com/p06276891/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

The rest is here:

CF & CFRP Market Research Report by Carbon Fiber Materials, Resin Type, Manufacturing Process, End-use Industry, Region - Global Forecast to 2027...

Last year, the Camden Fairview Cardinals had one of their biggest football seasons in program history.

Behind every conference winning championship team, weaknesses can cause a team to fall short of its biggest goals. While the Cardinals had a highly efficient defense that competed with some of the most talented offenses in the conference, they did have some problems they're hoping to address during spring training.

One weakness that the Cardinals possessed was the trouble they had defending against mid-range-to-deep passing situations. That is something that the Cardinals' defense looked to improve when the off-season started. This year, the defensive backs for Camden Fairview are more experienced and persistent in locking down the opposing passing game.

The Cardinals are returning two defensive backs from last season, but each of the five starters in the 4-2-5 defensive front has already shown to be in excellent form. Junior Jabauree Lockhart and senior cornerback Arquavion Martin led a talented Cardinals secondary that strives to lock down the top impact receivers on the opposing team. They are joined by the other main cornerback in Matt Davis, safety/linebacker Jabari Spencer and safety Takorey McCoy.

Lockhart started at cornerback last season and is taking a special and pivotal role on secondary and defense this year. He will be the rover for the Cardinals' defense, enabling him to be flexible and play as either a linebacker or safety in certain schemes.

Last season, Lockhart accounted for 40 tackles, one sack, a team-high 16 pass breakups, three interceptions, two forced fumbles and two fumble recoveries. His ability to scout the ball and read the quarterback's eyes in passing situations makes him one of the most reliable zone coverage players for the Cardinals. He is more efficient on covering bigger and more aggressive receivers, which can make him win at press at the line of scrimmage.

Martin is another defensive back that is switching from cornerback to the hybrid linebacker/safety position. Defensive coordinator Devin Ball made the switch as Martin can play more inside pass coverage.

"Arquavion has been bumped to the other spot, to a safety/linebacker hybrid, but he plays more coverage duty stuff. We play him to the strength; both of them are savvy, both of them (including Lockhart) are talented. I expect them to be the best safeties in the conference this year," Ball said.

McCoy will be the Cardinals' lone safety, often deep in the secondary. He will often be the one-man safety that plays a lot of zone coverage against deep passing situations. His ability to read the plays and the receivers' routes after the ball has been snapped is a huge asset to the Cardinals' pass defense. Ball said McCoy put on 10-15 pounds of muscle during the off-season and looks to be a huge playmaker for the Cardinals' defense.

Davis and Spencer are the team's primary man-coverage cornerbacks as the defensive backs will contain the outside deep receivers of the opposing offense. Ball complimented the quick twitch of Spencer's movement, which allows him to turn his hips and stay on his assigned man. Spencer is also highly aggressive at the line of scrimmage, which is good for press-man coverage to go along with his speed.

While Davis is one of the smallest-sized players by height for Camden Fairview, he is not a cornerback that loses contested catches. Davis possesses speed and superior athleticism and the surprising ability to create big hits to cause pass breakups and make open-field tackles. He possesses the athleticism to create pass disruptions in the air and swat the ball away. His speed, athleticism and determination make him a lockdown corner.

"Matt came to us to us this year, he is a late bloomer. Last year, he had some things going on off the field; we understand that in this world of this nature, we know kids have struggles. We rode it out with him through the school year to make sure he was good," Ball said. "He may be the smallest guy on the field, and the cliche is about the dynamite, but he brings a boom, and he has a great feel for the ball. Excellent in coverage, you see him out there against Jarvis Reed today and he did some special stuff for us."

This entire secondary for Camden Fairview already has asserted their presence in practices against this incredibly talented and loaded receiver corps. They look to get better throughout the Spring Training and this summer as they prepare for the 2022 season kicks off.

Read more:

Experienced defensive backs for CF thriving this off-season - Camden News

NEWS STORY. 22/05/2022

Today marks 37 years sinceReal Madrid lifted their first everUEFA Cup. On 22 May 1985, our team got their hands on the trophy at theSantiago Bernabu when they beat Hungarian side Videoton. In the first leg, the madridistas set themselves well on the way to the title with a 3-0 win thanks to goals forMchel, Santillana andValdano. The result was enough to see them lift the cup despite a 1-0 loss in the second leg.

On their way to the final, Madridknocked out Wacker Innsbruck, Rijeka, Anderlecht, Tottenham and Inter Milan. It was a historic campaign which included three unforgettable Santiago Bernabu comebacks. The first was a 3-0 win over Rijeka following a 3-1 loss in the opening leg. The second was even more impressive, having fallen to a 3-0 loss to Anderlecht, our boys produced a remarkable 6-1 win in the return fixture. The last, in the semi-finals, saw the team eliminate Inter (3-0) despite having lost 2-0 in Milan. On an individual level,Santillanawas the team's leading scorer, with 5.

FIRST LEG (8/5/1985)0-Videoton:P. Distzl, Borsanyi, L. Distzl, Csuhay, Horvath, Palkovics, Vegh, Wittmann, Vadasz, Novath (Gyenti, 62) and Burcsa.3-Real Madrid:Miguel ngel, Chendo, Camacho, Sanchs, San Jos, Mchel, Gallego, Stielike, Valdano, Butragueo (Juanito, 80) and Santillana (Salguero, 86).

Goals:0-1(min. 32):Mchel.0-2(min. 77):Santillana.0-3(min. 89):Valdano.

SECOND LEG (22/5/1985)0-Real Madrid:Miguel ngel, Chendo, Camacho, Sanchs, San Jos, Mchel, Gallego, Stielike, Valdano (Juanito, 58), Butragueo and Santillana (Salguero, 86).1-Videoton:P. Distzl, Vegh, Csuhay, L. Distzl, Horvath, Burcsa, Csongradi (Wittmann, 58), Vadasz, Majer, Szabo and Novath (Palkovics, 52).

Goals:0-1(min. 87):Majer.

See more here:

The 37th anniversary of Real Madrid's first UEFA Cup - Real Madrid CF

By Jessica Patrick, WRAL senior multiplatform producer

May is Cystic Fibrosis Awareness Month.

I talked to an expert -- Dr. Stephanie Duggins Davis, a pediatric pulmonologist, chair of the UNC Department of Pediatrics and physician-in-chief of UNC Childrens Hospital -- to better understand what a CF diagnosis means for families.

Q: What is Cystic fibrosis (CF)?

CF is a chronic, inherited disease that is diagnosed at birth. The disease progresses through a patient's lifetime. It can result in trouble breathing, lung infections, digestive issues, weight loss and diabetes, among other complications.

People with CF have trouble clearing mucus from their lungs and airways, and around 80% to 85% of patients experience problems with digestion.

As a chronic disease, CF impacts multiple systems in the human body. There is no cure, but treatments have improved greatly in recent years, resulting in a longer lifespan for many patients.

Treatment begins early in life and consists of a care team of nutritionists, respiratory therapists, physical therapists, pharmacists, social workers, physicians and psychologists working together to care for patients and their families.

Q: What has changed about CF treatment in the last three decades?

According to Davis, lifechanging progress has been made in the medical care and prognosis for CF patients.

Decades ago, babies and children weren't diagnosed with CF until symptoms began to appear, but today, CF is identified at birth when a small blood sample is collected from newborn babies, usually in the delivery room.

Before a blood test was used to detect CF, babies would present with serious symptoms, including failure to thrive or trouble breathing.

In present day, earlier detection means babies can begin treatment right away, including the administration of enzymes (given orally) that aid in digestion. The enzymes help children achieve proper nutrition and weight gain, a crucial component of CF monitored in patients, especially during those earlier years.

"We're able to more aggressively treat these children right away," Davis explained. "And that's really important because we know that adequate nutrition leads to better lung function."

Q: What is the prognosis for CF patients?

Another hopeful sign and the result of research is that many CF patients are living twice as long as they used to.

"There's a lot of hope now, because we have fantastic drugs to help treat patients with CF. The mean average age for survival is much longer than it was two decades ago," Davis said. "It's absolutely amazing how well patients are doing."

Davis recalls a much different time earlier in her career when she would treat very sick children with CF in the hospital.

"In the 1990s, sometimes, we'd see teenagers dying in the hospital. It's been a medical miracle ... we hardly admit children to the hospital anymore with CF. That's how much healthier they are," she said.

Although it varies, most CF patients today are living to be in their late 40s or 50s, Davis explained. When they are first diagnosed during infancy, she is now able to tell young parents their children may outlive them.

"That instills hope for these parents," she said.

Q: How often do babies and children with CF have to go to the doctor?

Babies diagnosed with CF typically visit a pediatric pulmonologist every month to every other month during their first year of life.

"It's because we know that weight gain is so important," Davis explained. "During the first year, we educate the families about CF. Then as they move into the preschool years, we spread out [the appointments]."

Q: What does treatment look like over a patient's lifetime?

Babies who have difficulty digesting food and suffer from pancreatic insufficiency are treated with enzymes from birth. Patients are also prescribed specialized vitamins. Patients may be treated with modulator drugs, which are targeted to specific types of genetic mutations associated with CF.

Families will also learn the importance of airway clearance, which helps to clear mucus from their child's lungs.

The airway clearance can be performed manually using physiotherapy, when a parent or caregiver pats on the patient's chest and back to clear mucus.

By the age of two, patients can be fitted for a special vibrating vest that works to clear mucus from the airways. This is a more convenient option for older kids, teenagers and adults with CF.

Q: Will you describe the quality of life for a child with CF?

Children with CF should attend school and participate in all types of activities including sports, Davis said.

"We tell families we want to make sure the patients do not become a vulnerable child. Send them to school. If they want to be an athlete, put them out on the soccer field or put them in other types of sports," she said.

Davis said children with CF can have a relatively normal day, although they may use their airway clearance vest in the mornings and evenings and they have to take daily medications along with enzymes to digest food.

It's okay -- even good -- for patients to be around other children. However, children with CF are asked to stay several feet away from other children with CF, because bacteria may be passed back and forth between children affected by this disease.

Q: What happens as patients get older?

As children get older and approach their teenage years, care also focuses on mental health, with experts screening both patients and their families.

"That is really important because if you're depressed due to a chronic disease, you're not going to be very motivated to do your chest physiotherapy and take all your medicine," Davis said.

Some patients with CF will develop diabetes, and an endocrinologist will join the treatment team.

As CF progresses, specialized drugs called modulators can be used in some patients. Doctors are still researching and learning more about modulator drugs -- including when to introduce them and when other types of medications may be stopped once modulators are started. The results are promising, Davis said, and since they are administered in a pill form, it's less complicated for patients.

Despite a lifetime of medicines and airway clearance, most CF patients are able to thrive for much of their adulthood.

"Many patients get married, have children, have normal jobs, go to college. Again, it looks very different than it did three to four decades ago," Davis said.

Q: How common is CF?

According to Davis, CF is prevalent in about 1 in 2,500 to 1 in 3,400 Caucasian or white infants. While CF is equally prevalent in men and women, it is more common in Caucasian babies than in other races and ethnicities.

Q: Is there anything else people should know?

Davis once again referenced how much better life is now for patients with CF and their families.

The advances in medicine and CF treatment are largely due to funding and research by the National Institute of Health and the Cystic Fibrosis Foundation, which was actually started by the family of children inflicted with this disease.

"The Cystic Fibrosis Foundation spent a lot of money and partnered with pharmaceutical companies to try to identify these specific modulators that have made such a difference for these families," Davis said.

Davis said it has been an honor to treat patients and families over the years while participating in life-changing research.

"It's the partnership between the care team, the family and the Cystic Fibrosis Foundation working together to care for these children and to change the face of CF," she said. "I think it's been an example of what you can really do in chronic disease when money is put forth for research and you all work together."

People can give to the Cystic Fibrosis Foundation online or register for one of three Great Strides walking events in Raleigh, Durham and Chapel Hill on May 14.

More:

Q&A: How a Cystic fibrosis diagnosis has changed in recent years - WRAL News

Its a Friday night in February, and Im talking on the phone with Mark McGovern, the father of Bryant attackman Logan McGovern.

His son lives with cystic fibrosis. He thrives. Hes a starting college athlete and a team leader and by all accounts everything youd want in a son, brother and teammate.

I explained to Mark my personal connection with CF before we started talking about his son.

About an hour into the conversation, he asked, What was your cousins name?

Her name Mandy. She died in January 2012 after her battle with CF, a rare genetic disease. She was two months younger than me only 26 at the time of her death.

With CF, it was a constant battle. I remember a sleepover at her house when we were around elementary school-age, us kids all sleeping on the floor in the family room, when she had a CF episode. Her coughing got worse and worse, and the at-home breathing remedies didnt help. My brother and I had to rush home in the middle of the night; she and my aunt went to the hospital.

There was a constant array of nebulizers and breathing treatments masks and gadgets no child should be so familiar with. As she got older, her lung function got progressively worse. She eventually needed to cart around a canister of oxygen until her lungs were so battered and the transplant list was so long that she passed away.

Thank you, Mark said. People like her, they all participated in what ended up happening for someone like Logan. We wouldn't have known what we knew about CF without what she went through back in the day.

I understand this is a dark start to a piece for a lacrosse website, but its meant to share a story of hope: A few years after she died, the first medicines to attack cystic fibrosis were gaining approval. Logan McGovern was part of a smaller subset of CF patients for which the first drugs were effective. He received the medicine, and his lung function improved almost instantly, and he went on to have an illustrious high school lacrosse career at Darien (Conn.) and is currently thriving in a starting role at Bryant.

He allowed me to share his story here.

When my cousin had CF, living until your mid-20s was the norm. Mark McGovern had a childhood friend who had it and died at 16. My cousin did the right things. She did her hours of treatments each day. In high school, she was featured in a local newspaper for working as a lifeguard at a community pool despite the disorder. The timing was just off for her.

The Cystic Fibrosis Foundation, the Boomer Esiason Foundation and others have brought a rare disease to the forefront. The CF walks my family participated in when I was little made some difference.

Heres a call to action: May is Cystic Fibrosis Awareness Month. Please visit cff.org or esiason.org and learn a little bit. And watch and appreciate Logan on the field.

You know, it would be a hell of a story if Logan and Coach Pressler won a national championship together, Mark says. A long shot, but, you know, Logan was a long shot, still is a long shot.

Read more about Logan here. He and Bryant will play in the NEC Semifinals on Thursday.

See the original post:

Kinnear: Hope, Turning CF Into 'Cure Found' and Betting on the Long Shot - insidelacrosse.com